| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 77.86 mm | 77.86 mm | 77.86 mm | 77.86 mm | 77.86 mm | 77.86 mm |
| Cash burn (monthly) | (no burn) | 3.27 mm | 6.73 mm | 7.77 mm | 7.03 mm | 6.17 mm |
| Cash used (since last report) | n/a | 95.03 mm | 195.86 mm | 225.91 mm | 204.54 mm | 179.51 mm |
| Cash remaining | n/a | -17.17 mm | -117.99 mm | -148.04 mm | -126.68 mm | -101.65 mm |
| Runway (months of cash) | n/a | -5.3 | -17.5 | -19.1 | -18.0 | -16.5 |
| 13F holders | Current |
|---|---|
| Total holders | 4 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 38.23 mm |
| Total shares | 8.48 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| New Enterprise Associates 16 | 4.29 mm | $30.10 mm |
| Venrock Healthcare Capital Partners II | 2.39 mm | $8.13 mm |
| Pivotal bioVenture Partners Fund I | 1.79 mm | $0.00 |
| LLY Eli Lilly and | 100.00 | $1.00 k |
